Biotech RadarJobs updated

COMPANY

Olatec Therapeutics

olatec.com ↗

Clinical Phase 3

Keywords: inflammatory diseases Acute Gout Flare Gout Attack Gout Flare Gouty Arthritis Gout Arthritis Joint Pain Schnitzler Syndrome Covid19 Cytokine Release Syndrome Systolic Heart Failure Osteoarthritis Osteoarthritis of the Knee OLT1177 Dapansutrile

Profile checked Oct 10, 2026

8Trials (company is sponsor)

Timeline

  1. Trial start Phase 2/Phase 3: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare source ↗
  2. Trial start Phase 2: Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome source ↗
  3. Trial start Phase 1: Study of Dapansutrile Capsules in Heart Failure source ↗
  4. Trial start Phase 2: Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome source ↗
  5. Trial start 1: Phase 1 Safety and PK Study of OLT1177 Capsules source ↗
  6. Trial start Phase 2: Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain source ↗
  7. Trial start 2: Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee source ↗
  8. Trial start 1: Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT05658575Study of Dapansutrile Tablets in Subjects With an Acute Gout FlarePhase 2/Phase 3RecruitingJan 6, 2023Dec 31, 2026 (estimated)
NCT03595371Pilot Study of Dapansutrile Capsules in Schnitzler's SyndromePhase 2TerminatedMay 15, 2018May 29, 2018 (actual)
NCT04540120Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release SyndromePhase 2TerminatedSep 24, 2020Jul 28, 2022 (actual)
NCT03534297Study of Dapansutrile Capsules in Heart FailurePhase 1CompletedMay 16, 2018Nov 21, 2019 (actual)
NCT02104050Study of OLT1177 Gel to Treat Moderate to Severe OA Knee PainPhase 2Completed2014-042015-08 (actual)
NCT02134964Phase 1 Safety and PK Study of OLT1177 Capsules1Completed2014-062014-12 (actual)
NCT01768975Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee2Completed2013-012013-08 (actual)
NCT01636141Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects1Completed2012-062012-08 (actual)
Feedback